|
Drug Name: compound tablet
English: Compound Sulfamethoxale Dispersible Tablets
Pinyin:
main components: major components of the goods: sulfamethoxazole (chemical called 4 - Amino-N - (5 - methyl -3 - isoxazole yl) -- benzene sulfonamide) (trimethoprim chemical called 5 - [(3,4,5 - three methoxyphenyl) - methyl] 2,4 - pyrimidine diamine)
traits: Profiled white tablets.
pharmacological effects: 1. Compound sulfamethoxazole can warfarin (warfarin) anticoagulation enhanced role, it should monitor the prothrombin time.
2. Goods from the plasma protein binding site replacement of certain drugs. Result: 1 for the oral hypoglycemic drugs can hypoglycemic effect intensified; â‘?methotrexate and inhibition of bone marrow increase; â‘?can extend the half-life of phenytoin.
3. Some drugs, such as acid-Son, dicoumarol and salicylic acid from the plasma protein binding site replacement of acid A oxazoline.
4. Sulfa drugs and Thiazide diuretics at the same time applications more easily thrombocytopenia.
Pharmacokinetics: sulfamethoxazole (SMZ) completely absorbed after oral administration, administration of absorption of about 90%, 3.78 ± 1.47 after administration hours of peak plasma concentration. After absorbing widely distributed in the body tissues and blood and easy to penetrate the blood-brain barrier and the placental barrier. Performance half-life of 5.86 ± 1.30 hours. The goods mainly in the liver metabolism without the antibacterial activity of acetylation, but still SD toxicity. Liver dysfunction, decreased metabolism. After administration of the goods within 24 hours of the urine from a phony delivery of 16 ~ 33%, about 30% acetylated form of discharge.
trimethoprim (TMP) completely absorbed after oral administration, administration of absorption of about 90%, the peak plasma concentration after administration reached 0.87 ± 0.51 hours. After absorbing widely distributed to organizations and body fluids, cut through the blood-brain barrier placental barrier. Half-life of 6.10 ± 0.61 hours, anuria, 20 ~ 50 hours. The goods delivery about 24 hours after administration of excluding 40 to 60%, 80 to 90% of drugs from phony, and the remaining part to the form of metabolites from.
indications: apply to the goods-sensitive Escherichia coli, Klebsiella pneumoniae isolates, Proteus bacteria survived in the treatment of urinary tract infections. Also for the treatment of the following diseases: Haemophilus influenza or pneumonia caused by bacteria in children with acute otitis media; Haemophilus influenza or pneumococcal cause of adult acute exacerbation of chronic bronchitis; Freund's and Soong's within bacterial dysentery caused by Shigella; Pneumocystis carinii infection.
usage and consumption: Warm water dispersed after oral administration may also obtain the entire film.
common in adults: the treatment of bacterial infections, a two oral, once every 12 hours. The treatment of parasitic infections such as Pneumocystis carinii pneumonia, one two, one every six hours.
commonly used in children: the treatment of bacterial infections, 40 kg body weight of infants and children an oral per kg body weight / 20, once every 12 hours, more than 40 kg of body weight of children with adult dose of common. Babies born less than a month using this ban.
adverse reaction: 1. Anaphylaxis is more common, may be in the drug eruptions, severe exudative can occur erythema multiforme, exfoliative dermatitis and epidermolysis bullosa, atrophic dermatitis. Performance is also enhanced light sensitivity, drug fever, joint and muscle pain, fever-like disease, serum response.
2. There will be of neutropenia, leukopenia, thrombocytopenia disease and aplastic anemia: patients can be manifested as angina, fever, pale and bleeding tendency. Therefore, sulfa drugs should be periodic checks of systemic blood around and found abnormal timely withdrawal.
3. There will be hemolytic anemia and Hemoglobinuria. A lack of glucose-6-phosphate dehydrogenase patients with sulfa drug-prone, in newborns and adults than in children seen.
4. There will be the neonatal hyperbilirubinemia and Kernicterus: As the sulfa drug and bilirubin competitive protein binding site, free of bilirubin can be increased. Because of imperfections neonatal liver function, bilirubin metabolism slow, so more prone to hyperbilirubinemia and neonatal jaundice, dual Kernicterus can occur.
5. Can cause liver damage: can occur jaundice, liver dysfunction, severe acute liver necrosis can occur. Therefore, in patients with liver dysfunction should avoid sulfa drug application or anti-systemic.
6. May cause kidney damage: crystallization can occur urine, hematuria and urinary tube. Treatment should be using this as a long, large dose of sodium bicarbonate-to-date with the clothes and water to prevent adverse reactions. The treatment of at least 2-3 times a week urine routine inspection. Crystal found to be hematuria or urinary sodium bicarbonate and drink a lot of water, until the crystallization of urine and urine disappeared. Water loss, shock and elderly patients should be using this prone to cause kidney damage, should avoid using this or anti.
7. There are nausea, vomiting, decreased counters, diarrhea, headaches, fatigue, symptoms generally minor and do not affect continued medication.
8. Goiter and dysfunction happen occasionally.
of taboos: right sulfa drug allergies, and pregnant women prohibited.
Note: 1. Cross-allergic reaction to a sulfa drug was allergic patients to other sulfa drug allergies may.
2. Right furosemide Sulfones, Thiazide diuretics, sulfonylurea, carbonic anhydrase inhibitor showed allergy patients can be allergic to sulfa drug.
3. Sulfa drugs can pass through the placenta barrier blood in the fetal blood and bilirubin competitive binding site, free of increased bilirubin, a nuclear hyperbilirubinemia and jaundice may therefore not using this late pregnancy.
4. Sulfa drugs can be secreted in the milk, milk concentrations up to maternal plasma concentration of 50 to 100%, drugs may have an impact on the infant. Sulfa drugs in the glucose -6 - phosphate dehydrogenase deficiency in the newborn lead to the application of hemolytic anemia may occur. In light of the above reasons, breast-feeding women should not be using this.
5. The sulfa drug can cause hemolytic nuclear neonatal jaundice and other side effects, so it is not appropriate for the general use as newborns.
6. Renal dysfunction in patients, such as creatinine clearance rate >30ml/min, would still be able to provide conventional and creatinine clearance rate of 15 ~ coefficients, constant halved, <15ml/min creatinine clearance rate, it is not appropriate to use.
7. Should anti following: lack of glucose -6 - phosphate dehydrogenase, liver dysfunction, hematoporphyrin of.
8. The attention to the treatment of inspection: 1 whole blood as inspection, and often accept more of the patients is particularly important;
â‘?treatment of regular urine screening (every 2 to check on the 3rd a conventional urine) to detect high-dose therapy or treatment may occur when the crystallization of urine.
specifications: each containing: 0.4 g sulfamethoxazole, trimethoprim 0.08.
Storage: shading, sealing preservation.
Validity: tentative 2002.
prescription drugs:
Warning:The information is only as a reference for new drug researcher and the patients or doctors can't use it as prescription basis!
Notice:Each item can have many explanations from different angels. If you want grasp the item comprehensively,please see below "more details data". |
Home Products Search Properties Search ä¸æ–‡ç‰ˆ